1
|
Cavazzini G, Colpani F, Cantore M, Aitini E, Rabbi C, Taffurelli M, Pari F, Bellomi A, Bertuzzi A, Smerierl F. Breast Metastasis from Gastric Signet Ring Cell Carcinoma, Mimicking Inflammatory Carcinoma. A Case Report. Tumori 2018; 79:450-3. [PMID: 8171750 DOI: 10.1177/030089169307900617] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
We report a case of breast metastasis of signet ring cell gastric cancer clinically presented as a primary inflammatory carcinoma. Metastases to the breast are uncommon; review of the literature demonstrated only 300 cases. The clinical and radiographic features of the metastatic lesion were unlike those reported in the literature. Although a primary signet ring cell breast carcinoma was described, the pathologic patterns of the breast lesion, here reported, lead us to conclude this was a metastasis and not another primary tumor.
Collapse
Affiliation(s)
- G Cavazzini
- Medical Oncology Department, Ospedale Civile Carlo Poma, Mantova, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Aitini E, Rabbi C, Mambrini A, Cavazzini G, Pari F, Zamagni D, Cantore M, Pagani M, Sorio M, Lusenti A, Adami F, Smerieri F. Epirubicin, Cisplatin and Continuous Infusion 5-Fluorouracil (ECF) in Locally Advanced or Metastatic Gastric Cancer: A Single Institution Experience. Tumori 2018; 87:20-4. [PMID: 11669552 DOI: 10.1177/030089160108700105] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Aims and Background The role of chemotherapy in locally advanced or metastatic gastric cancer has been controversial, but chemotherapy has recently been shown to relieve tumor-related symptoms, improve quality of life and prolong survival when compared with best supportive care. Furthermore, palliative chemotherapy is also cost-effective. “Second-generation” combination chemotherapy regimens were developed in the 1980s with high activity in advanced or metastatic gastric cancer (EAP, FAMTX, PELF, ECF). In randomized studies, EAP demonstrated no difference in activity but a significantly higher overall toxicity and toxic death rate than FAMTX, and the ECF (epirubicin, cisplatin, 5-fluorouracil) regimen gave a survival and response advantage, tolerable toxicity, better quality of life and was more cost-effective than FAMTX. Methods Sixty patients with locally advanced or metastatic gastric cancer were treated with the ECF regimen (21 weeks of 5-fluorouracil given by continuous infusion through a central line at 200 mg/m2 for 24-hr combined with cisplatin at 60 mg/m2 iv and epirubicin at 50 mg/m2 iv beginning on day 1 and repeated every 3 weeks for 8 courses). There were 42 males and 18 females, with a median age of 64 years (range, 40-74). The median performance status was 1. The histologic type was adenocarcinoma in 44 patients and undifferentiated carcinoma in 16 (27%). Three patients had locally advanced disease (5%) and 57 had metastatic disease (95%). Seven patients (12%) had received prior chemotherapy for advanced disease. Results All patients were assessable for toxicity and 55 for response (5 had insufficient treatment). Toxicity was mild or moderate, and there was no toxic death. Incidence of WHO toxicity ≥ 2 was nausea and vomiting in 3%, mucositis in 3%, leukopenia in 7%, anemia in 3%, and thrombocytopenia in 2%. Port-a-Cath toxicity was thrombosis in 4, dislocation in 2 and infection in 3 patients. Seven complete responses and 13 partial responses (overall response rate, 36%) were achieved, with a response rate of 39% in untreated and 17% in pretreated patients. Nine patients (16%) had stable disease and 26 (47%) progressive disease. Most patients felt symptomatically improved on ECF. Conclusions Our study confirms that the ECF regimen has a favorable pattern of toxicity and is feasible on an outpatient basis. However, it did not confirm the high response rate reported in other phase II trials.
Collapse
Affiliation(s)
- E Aitini
- Medical Oncology and Hematology Department, Carlo Poma Hospital, Mantua, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Abstract
Gastrointestinal autonomic nerve (GAN) tumor is an uncommon specialized form of gastrointestinal stromal tumor (GIST). We report the case of a 46-year-old man affected by this tumor. The neoplasm arose from the sigmoid colon. The patient underwent surgery but eight months later an omental relapse occurred. A second laparotomy was successfully performed and the patient is free of disease at 21 months of follow-up. To our knowledge this is the first case of a large bowel GAN tumor described in the literature.
Collapse
Affiliation(s)
- F Pari
- Department of Oncology and Hematology, Ospedale Carlo Poma, Mantua, Italy.
| | | | | | | | | | | |
Collapse
|
4
|
Bidoli P, Zilembo N, Cortinovis D, Mariani L, Isa L, Aitini E, Cullurà D, Pari F, Nova P, Mancin M, Formisano B, Bajetta E. Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study. Ann Oncol 2007; 18:461-7. [PMID: 17110590 DOI: 10.1093/annonc/mdl415] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Many patients with advanced non-small-cell lung cancer (NSCLC) do not tolerate cisplatin-based regimens because of its nonhemathological toxicity. PATIENTS AND METHODS We evaluated the response rate safety of new platinum analogue regimens, randomizing 147 patients with nonoperable IIIB/IV NSCLC to (i) carboplatin (area under the curve = 5 mg min/ml) on day 1 plus gemcitabine (GEM) (1000 mg/m(2)) on days 1 and 8 for six cycles; (ii) same regimen for three cycles followed by docetaxel (Taxotere) (40 mg/m(2)) on days 1 and 8 plus GEM (1250 mg/m(2)) on days 1 and 8 for three cycles; (iii) oxaliplatin (130 mg/m(2)) on day 1 plus GEM (1250 mg/m(2)) on days 1 and 8 for six cycles. RESULTS Intention-to-treat objective response rates were 25%, 25% and 30.6% in arms A, B and C, respectively. Median survival was 11.9, 9.2 and 11.3 months in arms A, B and C, respectively. Grade 3/4 neutropenia/anemia occurred in 29%/12.5%, 10%/16.5% and 8%/6% of arms A, B and C, respectively; grade 3/4 thrombocytopenia in 20.5%, 16.5% and 6%; grade 1/2 neurological toxicity in 43% of arm C. CONCLUSIONS Oxaliplatin/GEM (arm C) had similar activity to carboplatin/GEM (arm A), but milder hematological toxicity and may be worth testing in a phase III study against carboplatin/GEM in patients not suitable for cisplatin. The sequential regimen gave no additional benefit.
Collapse
Affiliation(s)
- P Bidoli
- Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori i, Milan, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Bidoli P, Cortinovis D, Isa L, Fusi A, Pari F, Cullurà D, Aitini E, Pessa S, Formisano B, Bajetta E. Preliminary results of a randomized phase II three-arm, multicentric study of carboplatin + gemcitabine (CBDCA + GEM), or oxaliplatin (L-OHP) + GEM, or sequential CBDCA + GEM→ docetaxel (DCT) + GEM in chemo-naive patients (pts) with advanced/metastatic non small cell lung cancer (NSCLC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7118] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- P. Bidoli
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| | - D. Cortinovis
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| | - L. Isa
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| | - A. Fusi
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| | - F. Pari
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| | - D. Cullurà
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| | - E. Aitini
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| | - S. Pessa
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| | - B. Formisano
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| | - E. Bajetta
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| |
Collapse
|
6
|
Santo A, Pedersini R, Pasini F, Terzi A, Pari F, Cartei G, Sibau A, Molino A, Maiorino A, Panza N, Oletti MV, Maluta S, Calabrò F, Cetto GL. A phase II study of induction chemotherapy with gemcitabine (G) and cisplatin (P) in locally advanced non-small cell lung cancer: interim analysis. Lung Cancer 2001; 34 Suppl 4:S15-20. [PMID: 11742697 DOI: 10.1016/s0169-5002(01)00400-7] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
BACKGROUND Gemcitabine-cisplatin (GP) combination is one of the most active and well tolerated regimens in advanced non-small cell lung cancer (NSCLC). The aim of this study is to evaluate the activity and toxicity of the GP regimen as a 21-day schedule in patients (pts) with stage IIIAN2-IIIB NSCLC. PATIENTS AND METHODS From October 1997 to July 2000, 47 pts entered the study: 43 were eligible (40 men and three women); median age was 61 years (range 45-73); ECOG PS 0-1; histology was squamous (20 pts), adenocarcinoma (12 pts), large cell (five pts), and undifferentiated (six pts); stage was IIIAN2 (14 pts, 32.56%), and IIIB (29 pts, 67.44%). Malignant pleural effusion or superior vena cava syndrome was criteria of exclusion. Induction treatment consisted of three cycles of GP (G 1250 mg/m(2) i.v. on days 1 and 8, and P 100 mg/m(2) on day 8 every 3 weeks). Responding and stable pts underwent surgery (S) and/or radiotherapy (RT). RESULTS Following a minimum of two cycles, 39 pts were evaluable for response and 42 for toxicity. Two pts had complete responses (CR; 5.2%), 24 had partial response (PR; 61.5%), eight had stable disease (SD; 20.5%), and five had progressive disease (PRO; 12.8%). WHO grades 3 and 4 anaemia, neutropenia and thrombocytopenia were observed in two, four and two pts, respectively; non-haematological toxicity was moderate. After induction, stable and responding pts received either RT (18 pts) or S+RT (13 pts). Among the 16 resected pts, a radical complete resection was possible in 13 cases (81.3%), whereas tumour down-staging was observed in nine pts (56.2%). CONCLUSION GP, as a 3-week neoadjuvant schedule, appears a safe and active regimen.
Collapse
Affiliation(s)
- A Santo
- Department of Medical Oncology, University of Verona, Verona, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Pari F, Zamagni MD, Carnevali C, Pagani M, Rabbi C, Cantore M, Cavazzini G, Aitini E, Smerieri F. [Systemic mastocytosis. A review of current diagnostic and therapeutic approaches]. Recenti Prog Med 1999; 90:169-72. [PMID: 10228358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
Mastocytosis is a heterogeneous group of disorders characterized by abnormal growth and accumulation of mast cells in skin, bone marrow, bone, gastrointestinal tract, liver, spleen and lymph nodes. Today, regarding its biological features, mastocytosis (with or without myeloid accompanying disorders) is considered to be a hematologic disease. The classification proposed by Metcalfe in 1991 is the most useful in caring for patients with mastocytosis. In this classification 4 groups are described: 1) indolent mastocytosis with or without extracutaneous involvement; 2) systemic mastocytosis with an associated hematologic disorder; 3) aggressive mastocytosis; 4) mast-cell leukemia. Cutaneous mastocytosis typically presents as urticaria pigmentosa or diffuse cutaneous mastocytosis and these patients usually have a benign course. On the contrary, systemic mastocytosis is a disease with an increased risk to develop an aggressive hematologic disorder. In these patients a second hematologic process, such as myeloproliferative or myelodysplastic syndrome or acute leukemia, may occur. These patients often present without skin involvement and they have a very poor prognosis. Mast cell is a medium-sized granulated cell releasing chemical mediators (histamine, heparin, protease and cytokines). Mast cells originate from pluripotent hemopoietic progenitor cells that express the CD34 antigen. Mast cells are present in the bone marrow and are distributed throughout the connective tissues. Recently a mast-cell growth factor (MGF) has been identified. Clinical symptoms occur from the release of chemical mediators and the pathologic infiltration of cells. Although no effective therapy for patients with Mastocytosis is known, some patients may benefit from corticosteroid and interferon alpha treatment. The present article gives an overview of current knowledge about the biology, heterogeneity and treatment of human mastocytosis.
Collapse
Affiliation(s)
- F Pari
- Divisione di Oncologia ed Ematologia, Ospedale Carlo Poma, Mantova
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Mambrini A, Cavazzini G, Pari F, Rabbi C, Cantore M, Zamagni MD, Amadori M, Riitano G, Schiavini A, Bosi A, Aitini E, Smerieri F. [Pulmonary metastasis from an eccrine carcinoma: thoracic perfusion with the aorto-caval stop-flow technique. Description of a clinical case]. MINERVA CHIR 1998; 53:441-5. [PMID: 9780638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
A case of a 64-year-old man with eccrine carcinoma arising from hand skin is reported. At the time of diagnosis he showed bilateral pneumonic metastases. Although the patient underwent two systemic chemotherapy lines, he showed further progressive disease of the lung. For this reason a third chemotherapy line was started through thoracic stop-flow infusion. In this way, a five month stable disease had been achieved. The patient died 7 months later for progressive disease. The rarity of this disease, the uncertain treatment, the feasibility and efficacy of thoracic stop-flow infusion are underlined and further studies are suggested.
Collapse
Affiliation(s)
- A Mambrini
- Divisione di Oncologia Medica, Azienda Ospedaliera C. Poma, Mantova
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Cantore M, Aitini E, Rabbi C, Cavazzini G, Bertani M, Pulica C, Campo S, Pari F, Mambrini A, Bezzi A, Zamagni D, Amadori M, Smerieri F. [Combined intra-arterial locoregional and systemic treatment of nonresectable hepatic metastases of colorectal carcinoma]. G Chir 1997; 18:235-9. [PMID: 9303640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Intra-arterial hepatic chemotherapy (LAHC) results in significantly higher response rate than the best systemic treatment of liver metastases from colorectal cancer, but no survival advantage has to date shown because of extra-hepatic progression. From June 1991 to December 1994, twenty patients with hepatic metastases from colorectal cancer were enrolled. All patients underwent laparotomy for the placement of an intra-arterial catheter into the gastroduodenal artery connected with a subcutaneous port. All patients underwent cholecystectomy and biopsy of liver lesion to confirm metastatic disease. Locoregional schedule was: 5-fluorouracil (5FU) 500 mg/sqm, epirubicin (EPI) 13 mg/sqm, mitomycin-C (MMC) 7 mg/sqm, in bolus every 3 weeks. Systemic therapy consisted of leucovorin 500 mg/sqm, over 2 hours and 5FU 600 mg/sqm in bolus every week. Treatment was planned over a six month period. The complete response (CR) plus partial response (PR) rate was 50% of the entire group. The median survival was 18 months and 1- and 2- and 3-year survival rates were 71%, 38% and 20% respectively. Prior to chemotherapy, LDH value and % of liver involvement were the only significant prognostic parameters. Toxicity was absent or mild and no patient stopped treatment because of side effects. Combined systemic and IAHC is an effective treatment for liver metastases from colorectal cancer, with a mild or moderate toxicity. However, more trials are needed, to improve the control of the extrahepatic disease.
Collapse
Affiliation(s)
- M Cantore
- Divisione di Oncologia, Azienda Ospedaliera C. Poma-Mantova
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Zamagni MD, Cantore M, Aitini E, Cavazzini G, Rabbi C, Forghieri M, Pari F, Mambrini A, Amadori M, Panzolato G, Smerieri F. [Testicular lymphomas. A clinico-pathological study of 5 cases and a review of the literature]. Recenti Prog Med 1996; 87:275-8. [PMID: 8766953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The authors describe five consecutive patients with testicular non Hodgkin lymphoma, evaluate the clinical and histological characteristics and underline the importance of a chemotherapy approach both at diagnosis and at relapse. A review of the literature is carried on and particularly about the prognostic factors, the correlation with Ebstein Barr virus and the more recent integrated therapeutical approaches.
Collapse
Affiliation(s)
- M D Zamagni
- Divisione di Oncologia Medica, Ospedale Carlo Poma, Mantova
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Rabbi C, Aitini E, Cavazzini G, Cantore M, Forghieri ME, Pari F, Zamagni D, Mambrini A, Amadori M, Smerieri F. Stomach preservation in low- and high-grade primary gastric lymphomas: preliminary results. Haematologica 1996; 81:15-9. [PMID: 8900847] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
BACKGROUND The optimal management of primary gastric lymphomas has yet to be defined. In the past surgery was advocated as the optimal first step for patients with PGL. Recently, an increasing number of studies suggest that chemotherapy is as effective as surgery. METHODS Fourteen patients with PGL were treated with chemotherapy alone. For patients with low-grade lymphoma, chemotherapy consisted of mitoxantrone 5 mg/sqm on days 1 to 3. Treatment courses were administered every 3 weeks up to a maximum of 6 cycles. Patients with high-grade lymphoma received chemotherapy according to the CHOP schedule every 4 weeks up to a maximum of 6 cycles. Two patients with high-grade lymphoma were treated as low-grade lymphoma patients (one because of age and poor performance status, the other because she refused chemotherapy that would cause hair loss). Two patients with low-grade lymphomas who did not respond to mitoxantrone were crossed over to CHOP. RESULTS All patients were evaluable for toxicity, 13 for response to therapy and survival. Toxicity was mild or moderate. Neither perforation nor hemorrhage was observed. Eleven patients achieved a complete remission (85%), 1 a partial remission (7.5%) and 1 underwent disease progression (7.5%). At a median follow-up of 12 months (range 4-44 months) all complete responders are alive and disease free. CONCLUSIONS Although the number of evaluable patients is too small to draw any final conclusions, chemotherapy seems to be as effective as surgery in PGL, and stomach preservation improves the quality of life of the patients.
Collapse
Affiliation(s)
- C Rabbi
- Department of Medical Oncology, Ospedale Carlo Poma, Mantua, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Aitini E, Cavazzini G, Cantore M, Rabbi C, Malaspina R, Truzzi R, Fazion S, Pari F, Mambrini A, Zamagni D. Carboplatin and Etoposide in an Out-Patient Schedule for the Palliation of Advanced Non-Small-Cell Lung Cancer. Tumori 1995; 81:429-31. [PMID: 8804469 DOI: 10.1177/030089169508100608] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Aims and background In Western countries, non-small-cell lung cancer is the most important cause of cancer-related death. To date, medical treatment for advanced stages remains of a palliative nature. Methods Forty-four patients with advanced non-small-cell lung cancer were treated in a phase II study with carboplatin and etoposide (each at 60 mg/m2 daily) in a 5-day schedule. Among 44 patients, 18 (40%) had stage IIIB disease and 26 (60%) had stage IV disease. Results Treatment was well tolerated, and the only significant side effect was alopecia. The overall response rate was 27% with 2 complete remissions; median survival time was 10.4 months. One of the 2 patients achieving a complete remission was still alive and disease free at 36 months from the start of therapy. An improvement of performance status was observed in 22 patients (50%). Conclusions The combination of carboplatin and etoposide using this schedule appears to be well tolerated and has some activity in the palliation of advanced non-small-cell lung cancer.
Collapse
Affiliation(s)
- E Aitini
- Department of Medical Oncology, Ospedale Carlo Poma, Mantova, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Rabbi C, Cantore M, Aitini E, Cavazzini G, Colpani F, Pari F, Morandi C, Colopi S, Lusenti A, Smerieri F. [Primary non-Hodgkin's lymphoma of the bone. Description of 2 cases]. Recenti Prog Med 1995; 86:294-8. [PMID: 7569286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Primary bone non Hodgkin's lymphomas (PBL) are approximately 5% of extranodal lymphomas and 5% of all primary bone tumors. A standard treatment has not been codified yet. The most received only radiotherapy but recently it was introduced combined modality treatment with radiotherapy plus chemotherapy or chemotherapy alone. The authors describe two cases of high grade PBL that received combined treatment with chemotherapy (VACOP-B regimen and monochemotherapy with mitoxantrone respectively) and radiotherapy. The patients achieved complete remission and up to day are alive and disease free at 33 and 15 months from the diagnosis respectively.
Collapse
Affiliation(s)
- C Rabbi
- UO di Oncologia Medica, Ospedale C. Poma, Mantova
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Aitini E, Cavazzini G, Cantore M, Rabbi C, Pari F, Mambrini A, Malavasi V, Smerieri F. [Current approaches in the medical treatment of advanced ovarian carcinoma]. Recenti Prog Med 1994; 85:587-90. [PMID: 7899684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Ovarian cancer is most frequently diagnosed at an advanced stage. In recent years there has been intense interest in the chemotherapy of this disease. About cisplatin, the most active agent in the treatment of advanced ovarian cancer, some questions are only partially answered, as the optimal dose, the duration of treatment, the role of ciplatin-based two-, three-, or four-drug regimens, the role of intraperitoneal therapy, the use of old and new drugs in cisplatin-resistant patients. Carboplatin is currently the most important cisplatin analogue with a toxicity pattern very different from that of the parent compound, but, up to date, the combination of these two drugs does not seem to be any better than standard chemotherapy. Among new drugs, three deserve particular attention: taxol, a natural produce from the bark of the Pacific yew Taxus brevifolia, taxotere, a taxoid obtained by semisynthesis from the needles of the European yew Taxus baccata and gemcitabine, a cytostatic agent with a close resemblance to cytosine-arabinoside. Anyway, new approaches must continue to be sought too: among these, probably gene therapy may offer the best mechanism to overcome both intrinsic and acquired drug resistance.
Collapse
|
15
|
Aitini E, Cavazzini G, Pasquini E, Rabbi C, Colombo F, Cantore M, Fattori PP, Pari F, Bertuzzi A, Smerieri F. Treatment of primary or metastatic pleural effusion with intracavitary cytosine arabinoside and cisplatin. A phase II study. Acta Oncol 1994; 33:191-4. [PMID: 8204275 DOI: 10.3109/02841869409098404] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Thirty-three patients with microscopically verified primary or metastatic malignant pleural effusion were studied: 7 had malignant mesothelioma and 26 metastatic pleural disease. The treatment was based on biochemical and clinical studies which show a synergy between cytosine-arabinoside (Ara-C) and cisplatin. These drugs were instilled in the pleural cavity at the dose of 100 mg for Ara-C and 100 mg/m2 for cisplatin. The cavity was drained after 4 h. If it was possible, the treatment was repeated weekly for 3 times and, after a 6-week rest, it could be started again with the same schedule. The overall response rate (complete plus partial remissions) was 74%. Toxicity was mild or moderate. We conclude that the combination of Ara-C and cisplatin is well tolerated and produces a high response rate in the treatment of malignant pleural effusions.
Collapse
Affiliation(s)
- E Aitini
- Department of Medical Oncology, Ospedale Carlo Poma, Mantova, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|